GlassScriptPhysician profile
Zurab Davili
NPI 1831391366
$12,018.73
in general payments reported to CMS, 2019-2025
54 companies · $5,333 in 2025
The $5,333 reported for 2025 was more than what 91% of Surgery providers received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $552 · 2020: $751 · 2021: $1,515 · 2022: $1,276 · 2023: $1,497 · 2024: $1,094 · 2025: $5,333.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,853 · Consulting Fee: $2,180 · Travel and Lodging: $1,558 · Education: $334.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,852.87 |
| Consulting Fee | $2,180.00 |
| Travel and Lodging | $1,557.60 |
| Education | $334.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $2,381.71 | 2021-2025 | |
| Procept Biorobotics Corporation | $1,254.87 | 2025 | |
| Astellas Pharma US INC | $963.40 | 2019-2025 | Xtandi |
| Teleflex LLC | $747.25 | 2021-2025 | Urolift |
| Janssen Biotech, INC. | $570.76 | 2020-2025 | Erleada, Carvykti, Rybrevant |
| Calyxo, INC. | $520.18 | 2021-2025 | Cvac Aspiration System |
| Sumitomo Pharma America, INC. | $479.30 | 2023-2025 | Orgovyx, Gemtesa |
| Axonics, INC. | $420.90 | 2020-2024 | Axonics |
| Antares Pharma, INC. | $357.33 | 2019-2025 | Xyosted, Tlando, Nocdurna |
| Abbvie INC. | $349.38 | 2020-2025 | Botox |
| Urogen Pharma, INC. | $343.02 | 2020-2025 | Jelmyto |
| Conmed Corporation | $323.96 | 2022-2023 | Airseal, Visiclear |
| Endo Pharmaceuticals INC. | $319.16 | 2019-2024 | Xiaflex, Aveed |
| Tolmar, INC. | $298.01 | 2023-2025 | Jatenzo, Eligard |
| Tolmar Pharmaceuticals, INC. | $247.44 | 2020-2022 |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zurab Davili listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.